文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

体外二氧化碳清除辅助低潮气量通气对急性低氧性呼吸衰竭患者90天死亡率的影响:REST随机临床试验

Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在急性低氧性呼吸衰竭机械通气患者中,体外二氧化碳清除辅助更低潮气量通气未降低90天死亡率,且无呼吸机天数更少、严重不良事件更多。

REST多中心随机开放标签试验纳入412例急性低氧性呼吸衰竭机械通气成人患者,比较体外二氧化碳清除辅助更低潮气量通气(至少48小时)与常规低潮气量通气。试验因无效性和可行性提前终止,可能把握度不足。

要点

  • 体外二氧化碳清除组严重不良事件更多(31% vs 9%),包括颅内出血9例(4.5%)vs 0例、其他部位出血6例(3.0%)vs 1例(0.5%)。
  • 共21例患者发生22起与研究装置相关的严重不良事件。
  • 试验因无效性和可行性提前终止(计划样本量1120例,实际412例),可能把握度不足以检测临床重要差异。

适用人群与场景

  • 成人(平均年龄59岁,35%女性)因急性低氧性呼吸衰竭接受机械通气,来自英国51个ICU,2016年5月至2019年12月纳入。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 干预组:体外二氧化碳清除辅助更低潮气量通气,至少持续48小时;对照组:常规低潮气量通气。
  • 原文未提及具体的潮气量目标、体外二氧化碳清除设备参数、抗凝方案或药物剂量。

红旗征与不能漏的情况

  • 体外二氧化碳清除组颅内出血9例(4.5%)vs 0例,其他部位出血6例(3.0%)vs 1例(0.5%),需警惕出血并发症。
  • 体外二氧化碳清除组严重不良事件发生率31% vs 9%,共21例患者发生22起装置相关严重不良事件。

研究设计与关键结果

  • 多中心、随机、分配隐藏、开放标签、实用性临床试验,51个英国ICU,412例成人急性低氧性呼吸衰竭机械通气患者(计划样本量1120例),因无效性和可行性提前终止。
  • 严重不良事件:体外二氧化碳清除组62例(31%)vs 常规组18例(9%),包括颅内出血9例(4.5%)vs 0例、其他部位出血6例(3.0%)vs 1例(0.5%);共21例患者发生22起装置相关严重不良事件。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验(RCT),开放标签,实用性设计。
  • 试验因无效性和可行性提前终止,样本量412例(计划1120例),可能把握度不足。

对床旁实践的改变

  • 对于急性低氧性呼吸衰竭机械通气成人患者,不应常规使用体外二氧化碳清除辅助更低潮气量通气以降低死亡率,因未显示获益且无呼吸机天数更少、严重不良事件(包括颅内出血)更多。
  • 该结果基于因无效性提前终止的试验,可能把握度不足,不能完全排除临床重要差异,但现有证据不支持该策略。
  • 原文未提及适用/不适用人群的进一步细化或常见陷阱。

指南或共识出处

  • 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT02654327,发表于JAMA。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: In patients who require mechanical ventilation for acute hypoxemic respiratory failure, further reduction in tidal volumes, compared with conventional low tidal volume ventilation, may improve outcomes.

OBJECTIVE: To determine whether lower tidal volume mechanical ventilation using extracorporeal carbon dioxide removal improves outcomes in patients with acute hypoxemic respiratory failure.

DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized, allocation-concealed, open-label, pragmatic clinical trial enrolled 412 adult patients receiving mechanical ventilation for acute hypoxemic respiratory failure, of a planned sample size of 1120, between May 2016 and December 2019 from 51 intensive care units in the UK. Follow-up ended on March 11, 2020.

INTERVENTIONS: Participants were randomized to receive lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal for at least 48 hours (n = 202) or standard care with conventional low tidal volume ventilation (n = 210).

MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality 90 days after randomization. Prespecified secondary outcomes included ventilator-free days at day 28 and adverse event rates.

RESULTS: Among 412 patients who were randomized (mean age, 59 years; 143 [35%] women), 405 (98%) completed the trial. The trial was stopped early because of futility and feasibility following recommendations from the data monitoring and ethics committee. The 90-day mortality rate was 41.5% in the lower tidal volume ventilation with extracorporeal carbon dioxide removal group vs 39.5% in the standard care group (risk ratio, 1.05 [95% CI, 0.83-1.33]; difference, 2.0% [95% CI, -7.6% to 11.5%]; P = .68). There were significantly fewer mean ventilator-free days in the extracorporeal carbon dioxide removal group compared with the standard care group (7.1 [95% CI, 5.9-8.3] vs 9.2 [95% CI, 7.9-10.4] days; mean difference, -2.1 [95% CI, -3.8 to -0.3]; P = .02). Serious adverse events were reported for 62 patients (31%) in the extracorporeal carbon dioxide removal group and 18 (9%) in the standard care group, including intracranial hemorrhage in 9 patients (4.5%) vs 0 (0%) and bleeding at other sites in 6 (3.0%) vs 1 (0.5%) in the extracorporeal carbon dioxide removal group vs the control group. Overall, 21 patients experienced 22 serious adverse events related to the study device.

CONCLUSIONS AND RELEVANCE: Among patients with acute hypoxemic respiratory failure, the use of extracorporeal carbon dioxide removal to facilitate lower tidal volume mechanical ventilation, compared with conventional low tidal volume mechanical ventilation, did not significantly reduce 90-day mortality. However, due to early termination, the study may have been underpowered to detect a clinically important difference.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02654327.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. McNamee JJ, Gillies MA, Barrett NA, et al. Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial. JAMA. 2021. PMID: 34463700. doi:10.1001/jama.2021.13374

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。